

Data for meta-analyses

IRLS Rating Scale Total Scores for Cabergoline, Treatment vs. Baseline

Study	Study Length	# Pts Completed	Dose, mg/d	IRLS Baseline Avg \pm SD	IRLS Cabergoline Avg \pm SD	P
Oertel, 2006 ⁶³	5 wks	20 each tx	2	31.2 \pm 5.4	7.5 \pm 15.3*	< 0.01
Stiasny-Kolster, 2004 ⁶⁴	52 wks	22 [†]	2.2 \pm 1.1	27.7 \pm 5.7	12.0 \pm 16.3*	< 0.001
Benes, 2004 ⁶⁶	6 mo	248	1.5	26.8 \pm 5.9	9.7 \pm 9.0	< 0.001
Zucconi, 2003 ⁶⁵	2 mo	10	1.1	23.1 \pm 5.9**	9.8 \pm 6.9	0.005

[†]Number of patients on 2 mg dose, out of 85 patients in complete dose-finding trial.

*Back calculated from difference data.

**After 1 week of placebo treatment (24.3 \pm 2.9 at baseline). tx, treatment.

IRLS Rating Scale Total Scores for Cabergoline vs. Placebo

Study	Study Length / # Pts Completed	Dose, mg/d	IRLS Comparison Avg (SD)	IRLS Cabergoline Avg (SD)	P
Cabergoline vs. placebo					
Oertel, 2006 ⁶³	5 wks / 40 (20 each tx)	2	-7.9 \pm 11.0	-23.7 \pm 11.2	0.0002
Stiasny-Kolster, 2004 ⁶⁴	5 wks / 44 (22 each tx)	2	-3.3 \pm 8.0	-15.7 \pm 11.9	< 0.001
Cabergoline vs. levodopa					
Trenkwalder, 2007 ⁶⁷	30 wks / 204	2-3 cabergoline 200+ L-dopa	-8.8 \pm 10.7	-15.6 \pm 10.8	< 0.0001
tx, treatment.					

IRLS Rating Scale Total Scores for Pramipexole

Study	Study Length / # Pts Completed	Dose quoted, mg/day	IRLS Baseline Avg (SD)	Δ IRLS Placebo Avg (SD)	Δ IRLS Pramipexole Avg (SD)	P
Large studies with placebo control						
Montagna 2011 ³⁶	12 weeks / 199 placebo, 203 pramipexole	0.125 to 0.75	Placebo: 25.8 ± 5.4 Pramipexole: 25.9 ± 5.2	-8.4 ± 8.3	-14.5 ± 7.4	< 0.0001
Ferini-Strambi, 2008 ³⁰	12 weeks / ITT 179 placebo, 178 pramipexole (278 completed)	0.42*	Placebo: 24.6 ± 5.7 Pramipexole: 24.2 ± 5.2	-9.6 ± 9.4	-13.4 ± 9.3	< 0.0001
Oertel, 2007 ³²	6 weeks / 115 placebo, 230 pramipexole (338 completed)	0.35**	Placebo: 24.9 ± 5.4 Pramipexole: 24.7 ± 5.2	-5.7 ± 9.6	-12.3 ± 9.1	< 0.0001
Winkelman, 2006 ³¹	12 weeks / 86 placebo, 80 pramipexole (281 total completed all doses)	0.5	Placebo: 23.5 ± 5.2 Pramipexole: 22.9 ± 5.1	-9.3 ± 9.3	-13.8 ± 8.9	< 0.01
Large study without placebo control						
Inoue 2011 ³⁷	6 weeks / 154 divided into 3 dose groups	0.25, 0.5 and 0.75	22.3 ± 4.7	N/A	-12.3 [‡] [95% CI: -13.4, -10.9]	Not stated
Small studies with placebo control						
Inoue 2010 ³⁴	6 weeks / 21 placebo, 20 pramipexole	0.125-0.75	Placebo: 25.1 ± 5.8 Pramipexole:	-6.4 ± 7.4	-16.1 ± 7.1	< 0.001

			23.4 ± 6.4			
Jama 2009 ^{35,39}	3 weeks / 21 placebo, 22 pramipexole	0.5 mg (0.125 to 0.75 tested)	Placebo: 22.9 ± 4.2 Pramipexole: 23.6 ± 3.7	-6 ± 9 [†]	-17 ± 9 [†]	< 0.0001
Partinen, 2006 ³³	3 weeks / 22 each pramipexole 0.5 mg and placebo (107 total completed all doses)	0.5	Placebo: 22.9 ± 4.2 Pramipexole: 23.6 ± 3.7	-6.1 ± 7.0	-17.0 ± 7.0	< 0.0001
Long-term trial data						
Inoue 2010 ³⁸	52 weeks / 140	0.125 to 0.75	22.3 ± 4.7	N/A	-17.4 ± 5.3	Not stated
Partinen 2008 ³⁹	26 weeks / 107	0.125 to 0.75	23.0 ± 4.3	N/A	-17.0 ± 5.5	Not stated

* Calculated from 0.125 mg for 15.4% (28/182), 0.25 mg for 33.0% (60/182), 0.5 mg for 26.9% (49/182), and 0.75 mg for 24.7% (45/182).

**Median dose.

[†]Calculated from SE data given.

[‡]Mean of all doses.

IRLS Rating Scale Total Scores for Ropinirole

Study	Study Length / # Pts Completed	Dose, mg/d	IRLS Baseline Avg (SD)	IRLS Placebo Avg (SD)	IRLS Ropinirole Avg (SD)	P
Adler, 2004 ⁴⁸	4 wks each / 22 each tx	4.6 ± 2.0	25.0 ± 7.0	24.7 ± 7.2	13.0 ± 12.0	< 0.001
				-0.3 ± 6.9	-12.0 ± 9.6	
Bliwise, 2005 ⁵²	2 wks / 13 placebo, 9 ropinirole	1.4	22.6 ± 4.6	16 ± 6*	14 ± 9*	ns
				-6.6 ± 5.1	-8.6 ± 6.7	

Bogan, 2006 ⁴⁹	12 wks /186 ropinirole, 191 placebo	2.1 ± 1.2	Ropinirole: 22.0 ± 5.0	11.9 ± 9.2 LOCF	8.4 ± 7.3 LOCF	< 0.001
			Placebo: 21.6 ± 4.8	-9.7 ± 7.3	-13.6 ± 6.2	
Trenkwalder, 2004 ⁵⁰	12 wks / 146 ropinirole, 138 placebo	1.9 ± 1.1	Ropinirole: 24.4 ± 5.75	-8.0 ± 8.7	-11.0 ± 8.7	0.0036
			Placebo: 25.2 ± 5.63			
Walters, 2004 ⁵¹	12 wks / 102 ropinirole, 107 placebo	1.5	Ropinirole: 23.6 ± 5.9	-8.7 ± 7.8	-11.2 ± 7.7	0.0197
			Placebo: 24.8 ± 5.4			
Other data not used in meta-analysis						
Garcia- Borreguero, 2007 ⁵⁶	1 year / 233 OC and 307 LOCF	1.9	22.0 ± 8.66	Not applicable	10.9 ± 7.71 OC	Not stated
					12.0 ± 8.60 LOCF	
Kushida, 2008 ⁵⁴	12 wks / 175 ropinirole, 184 placebo	3.1 ± 2.0 Divided doses	Not stated	-11 ± 13* OC	-15 ± 20* OC	< 0.001
Montplaisir, 2006 ⁵⁵	12 wks / 92	2.05 ± 1	Baseline = 24 weeks treated	+8.2	+4.1	0.0246
Allen, 2004 ⁵³	12 wks / 59	0.25-4.0	Adjusted treatment difference in favor of ropinirole at week 12 LOCF = -1.2			ns, P = 0.56

*Estimated from figure in paper, SD calculated from graph data. OC, observed case; LOCF, Last observation carried forward.

IRLS Rating Scale Total Scores for Rotigotine

Study	Study Length / # Pts Completed	Dose,* mg/d	IRLS Baseline Avg (SD)	IRLS Placebo Avg (SD)	IRLS Rotigotine Avg (SD)	P
Hening 2010 ¹¹⁰	6 mo / 99 placebo, 103 rotigotine	3.0	Placebo: 23.1 ± 5.1 Rotigotine: 23.6 ± 5.0	14.5 ± 8.0	9.3 ± 8.5	< 0.0001
				-9.0 ± 7.7	-14.3 ± 9.4	
Oertel 2010 ¹¹¹	4 wks / 20 placebo, 46 rotigotine	Mean 2.1	Placebo: 25.4 ± 6.3 Rotigotine: 26.3 ± 6.4	-9.9 ± 9.9	-16.5 ± 9.3	Not stated
Oertel, 2008 ¹⁰⁷	6 wks / 333 total-53 placebo, 64 rotigotine	3.0	Placebo: 28.0 ± 6.3 Rotigotine: 27.4 ± 6.1	18.7 ± 10.6	10.1 ± 8.6	< 0.0001
				-9.3 ± 8.6	-17.3 ± 7.4	
Stiasny-Kolster, 2004 ¹⁰⁸	1 wk / 62 total-14 placebo, 19 rotigotine	4.5	Placebo: 25.0 ± 18.7 Rotigotine: 25.9 ± 23.5	-8.0 ± 8.2	-15.7 ± 8.3	< 0.01
Trenkwalder, 2008 ¹⁰⁹	6 mo / 114 placebo, 112 rotigotine	3.0	Placebo: 28.1 ± 6.3 Rotigotine: 28.0 ± 5.9	-8.6 ± 9.6	-16.8 ± 9.5	< 0.0001

*Data for other doses are listed in the evidence table available online at <http://www.aasmnet.org/practiceguidelines.aspx>.

IRLS Rating Scale Total Scores for Gabapentin Enacarbil (GEn)

Study	Study Length / # Pts Completed	Dose, mg/d	IRLS Baseline Avg (SD)	IRLS Placebo Avg (SD)	IRLS Gabapentin Enacarbil Avg (SD)	P
Kushida 2009 ⁸²	12 wks / 92 placebo, 100 Gen	1200	Placebo: 22.6 ± 4.9	-8.8 ± 8.6	-13.2 ± 9.2	0.0003
			GEn: 23.1 ± 4.9			
Kushida 2009 ⁸⁶	2 wks / 24 each treatment (crossover)	1800	Placebo: 20.4	-1.9 ± 6.3	-12.1 ± 6.5	< 0.0001
			GEn: 20.4			
Walters 2009 ^{84*}	2 wks / 33 placebo, 33 Gen	1200	Placebo: 22.4 ± 4.6	-8.9 ± 7.7	-16.1 ± 7.93	< 0.0001
			GEn: 22.4 ± 4.4			
Ellenbogen 2011 ⁸⁸	52 wks / 376 in safety population	600-1800	23.2 ± 5.03	N/A	-16.8 ± 8.21 OC	Not stated
					-15.2 ± 8.85 LOCF	
Lee 2011 ⁸⁵	12 wks / 77/97 placebo, 104/115 GEn	600	Placebo: 23.8 ± 4.58	-9.8 ± 7.69	-13.8 ± 8.09	< 0.0001
			GEn: 23.1 ± 4.93			
	12 wks / 77/97 placebo, 98/113 GEn	1200	Placebo: 23.8 ± 4.58	-9.8 ± 7.69	-13.0 ± 9.12	0.0015
			GEn: 23.2 ± 5.32			

*Data for other doses are reported in the paper.